EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Plain Language Summary of a Publication: Rejoyn® (CT-152), a unique prescription digital treatment along with antidepressant medicine for people with clinical depression (the Mirai study)

Brian Rothman, Mary Slomkowski, Austin Speier, A. John Rush, Madhukar H. Trivedi, Shaheen E. Lakhan, Erica Lawson, Michael Fahmy, Daniel Carpenter, Dalei Chen, John P. Docherty, Ainslie Forbes

Therapeutic Advances in Psychopharmacology · 2026-11 · 16

DOI: 10.1177/20451253261499754 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 20.11.2026. Verfasst von Brian Rothman und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

What is this summary about? This summary describes the findings of a study that tested whether a new prescription digital treatment app called Rejoyn® (CT-152) could help people feel relief from their clinical depression when used in addition to their antidepressant medicine . People that were included in this study still had clinical depression even though they were being treated with antidepressant medicine. The study compared Rejoyn to a control app. The results were published in May 2025 in a medical journal ( Journal of Affective Disorders ). What is this plain language summary for? The purpose of this plain language summary is to help patients, caregivers, and healthcare providers understand the findings from the Mirai study. Who should read this summary? This summary can help adults aged 22 years and older with clinical depression, their family or caregivers, and their healthcare providers learn more about treatment options for clinical depression. Who sponsored this study? This study was sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. Click Therapeutics, Inc. was a co-developer . Where can I find the original article that this summary is based on? The original article ‘A digital therapeutic (CT-152) as adjunct to antidepressant medication: A phase 3 randomized controlled trial (the Mirai study)’ was published in the Journal of Affective Disorders . This article can be accessed for free at: https://www.sciencedirect.com/science/article/pii/S0165032725008353

Zitieren

APA

Rothman, B., Slomkowski, M., Speier, A., Rush, A. J., Trivedi, M. H., Lakhan, S. E., Lawson, E., Fahmy, M., Carpenter, D., Chen, D., Docherty, J. P., & Forbes, A. (2026). Plain Language Summary of a Publication: Rejoyn® (CT-152), a unique prescription digital treatment along with antidepressant medicine for people with clinical depression (the Mirai study). Therapeutic Advances in Psychopharmacology, 16. https://doi.org/10.1177/20451253261499754

Vancouver

Rothman B, Slomkowski M, Speier A, Rush AJ, Trivedi MH, Lakhan SE, et al. Plain Language Summary of a Publication: Rejoyn® (CT-152), a unique prescription digital treatment along with antidepressant medicine for people with clinical depression (the Mirai study). Therapeutic Advances in Psychopharmacology. 2026;16. doi:10.1177/20451253261499754

BibTeX
@article{Rothman2026,
  author = {Rothman, Brian and Slomkowski, Mary and Speier, Austin and Rush, A. John and Trivedi, Madhukar H. and Lakhan, Shaheen E. and Lawson, Erica and Fahmy, Michael and Carpenter, Daniel and Chen, Dalei and Docherty, John P. and Forbes, Ainslie},
  title = {Plain Language Summary of a Publication: Rejoyn® (CT-152), a unique prescription digital treatment along with antidepressant medicine for people with clinical depression (the Mirai study)},
  journal = {Therapeutic Advances in Psychopharmacology},
  year = {2026},
  volume = {16},
  doi = {10.1177/20451253261499754}
}
Kostenlos starten →